Sign in to fuzzto save your conversations, follow your research and come back anytime.
Windlas Biotech
WINDLAS
NSE
BSE
NSEBSESectorHealthcare
1,132.00
Loading chart…
NSEBSEThe Quarter story
The two most recent quarterly results, compared side-by-side.
Windlas Biotech shows steady revenue growth and margin stability, though rising input costs and trade segment weakness require attention.
Revenue grows from ₹210.1 Cr to ₹248 Cr from Q1 FY26 to Q1 FY27 — steady top-line momentum
COGS climbs from ₹129.7 Cr to ₹153 Cr from Q1 FY26 to Q1 FY27 — sustained input cost inflation
Gross Profit expands from ₹80.4 Cr to ₹95 Cr over five quarters — consistent volume increases
Trade Generics & Institutional Revenue drops from ₹53 Cr to ₹30 Cr from Q3 FY26 to Q1 FY27 — channel weakness
Generic Formulations CDMO Revenue climbs from ₹160.2 Cr to ₹207 Cr from Q1 FY26 to Q1 FY27 — core segment strength
Finance Costs spike from ₹1 Cr to ₹2 Cr from Q3 FY26 to Q1 FY27 — renewed debt servicing pressure
EPS rebounds from ₹7.12 to ₹8.46 from Q3 FY26 to Q1 FY27 — earnings recovery confirmed
Employee Expenses rise from ₹32.2 Cr to ₹37 Cr from Q1 FY26 to Q1 FY27 — continued workforce expansion
Gross Margin holds steady between 38.3% and 38.4% across the period — stable pricing power
Exports Revenue eases from ₹13 Cr to ₹11 Cr from Q3 FY26 to Q1 FY27 — export demand normalization
